Annotation Detail
Information
- Associated Genes
- RUNX1
- Associated Variants
-
RUNX1 MUTATION
RUNX1 MUTATION - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- In non-APL patients with AML (age 18-60), those who had mutations in RUNX1 had significantly shorter relapse-free survival following conventional post-remission treatment (repetitive cycles of high-dose cytarabine) than those treated with an allogeneic hematopoietic stem-cell transplantation (N=32) at first remission (4-year RFS; 0% vs 52%; P<0.0001).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/411
- Gene URL
- https://civic.genome.wustl.edu/links/genes/43
- Variant URL
- https://civic.genome.wustl.edu/links/variants/155
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Cytarabine
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 21343560
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cytarabine | Resitance or Non-Reponse | true |